Alkermes plc vs ADMA Biologics, Inc.: SG&A Expense Trends

SG&A Expense Trends: Alkermes plc vs ADMA Biologics, Inc.

In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Alkermes plc and ADMA Biologics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Alkermes plc consistently outpaced ADMA Biologics, Inc. in SG&A spending, with a peak in 2023 reaching nearly 690% higher than ADMA's expenses. This significant difference highlights Alkermes' aggressive investment in administrative and sales functions, potentially reflecting a strategy focused on market expansion and operational efficiency. Meanwhile, ADMA Biologics, Inc. has shown a steady increase in SG&A expenses, growing by over 1,100% from 2014 to 2023, indicating a robust scaling of operations. These trends provide valuable insights into the strategic priorities and growth trajectories of these two pharmaceutical giants.